|
1
|
Bettenworth D, Nowacki TM, Cordes F,
Buerke B and Lenze F: Assessment of stricturing Crohn's disease:
Current clinical practice and future avenues. World J
Gastroenterol. 22:1008–1016. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Satsangi J, Silverberg MS, Vermeire S and
Colombel JF: The Montreal classification of inflammatory bowel
disease: Controversies, consensus, and implications. Gut.
55:749–753. 2006.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Freeman HJ: Natural history and long-term
clinical course of Crohn's disease. World J Gastroenterol.
20:31–36. 2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Cosnes J, Gower-Rousseau C, Seksik P and
Cortot A: Epidemiology and natural history of inflammatory bowel
diseases. Gastroenterology. 140:1785–1794. 2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Cosnes J, Cattan S, Blain A, Beaugerie L,
Carbonnel F, Parc R and Gendre JP: Long-term evolution of disease
behavior of Crohn's disease. Inflamm Bowel Dis. 8:244–250.
2002.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Solberg IC, Vatn MH, Høie O, Stray N,
Sauar J, Jahnsen J, Moum B and Lygren I: IBSEN Study Group.
Clinical course in Crohn's disease: Results of a norwegian
population-based ten-year follow-up study. Clin Gastroenterol
Hepatol. 5:1430–1438. 2007.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Louis E, Collard A, Oger AF, Degroote E,
Aboul Nasr El Yafi F and Belaiche J: Behaviour of Crohn's disease
according to the Vienna classification: Changing pattern over the
course of the disease. Gut. 49:777–782. 2001.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Frolkis AD, Lipton DS, Fiest KM, Negrón
ME, Dykeman J, deBruyn J, Jette N, Frolkis T, Rezaie A, Seow CH, et
al: Cumulative incidence of second intestinal resection in Crohn's
disease: A systematic review and meta-analysis of population-based
studies. Am J Gastroenterol. 109:1739–1748. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Cosnes J, Nion-Larmurier I, Beaugerie L,
Afchain P, Tiret E and Gendre JP: Impact of the increasing use of
immunosuppressants in Crohn's disease on the need for intestinal
surgery. Gut. 54:237–241. 2005.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Louis E, Michel V, Hugot JP, Reenaers C,
Fontaine F, Delforge M, El Yafi F, Colombel JF and Belaiche J:
Early development of stricturing or penetrating pattern in Crohn's
disease is influenced by disease location, number of flares, and
smoking but not by NOD2/CARD15 genotype. Gut. 52:552–557.
2003.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Allez M and Lémann M: Role of endoscopy in
predicting the disease course in inflammatory bowel disease. World
J Gastroenterol. 16:2626–32. 2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Pernat Drobež C, Ferkolj I, Potočnik U and
Repnik K: Crohn's disease candidate gene alleles predict time to
progression from inflammatory B1 to stricturing B2, or penetrating
B3 phenotype. Genet Test Mol Biomarkers. 22:143–151.
2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Adler J, Rangwalla SC, Dwamena BA and
Higgins PD: The prognostic power of the NOD2 genotype for
complicated Crohn's disease: A meta-analysis. Am J Gastroenterol.
106:699–712. 2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Tolentino YF, Elia PP, Fogaça HS, Carneiro
AJ, Zaltman C, Moura-Neto R, Luiz RR, Carvalho Mda G and de Souza
HS: Common NOD2/CARD15 and TLR4 polymorphisms are associated with
Crohn's disease phenotypes in southeastern brazilians. Dig Dis Sci.
61:2636–2647. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Cleynen I, González JR, Figueroa C, Franke
A, McGovern D, Bortlík M, Crusius BJ, Vecchi M, Artieda M,
Szczypiorska M, et al: Genetic factors conferring an increased
susceptibility to develop Crohn's disease also influence disease
phenotype: Results from the IBDchip European project. Gut.
62:1556–1565. 2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Schnitzler F, Friedrich M, Wolf C,
Angelberger M, Diegelmann J, Olszak T, Beigel F, Tillack C,
Stallhofer J, Göke B, et al: The NOD2 p.Leu1007fsX1008 mutation
(rs2066847) is a stronger predictor of the clinical course of
Crohn's disease than the FOXO3A intron variant rs12212067. PLoS
One. 9(e108503)2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Cleynen I, Boucher G, Jostins L, Schumm
LP, Zeissig S, Ahmad T, Andersen V, Andrews JM, Annese V, Brand S,
et al: Inherited determinants of Crohn's disease and ulcerative
colitis phenotypes: A genetic association study. Lancet.
387:156–167. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Magro F, Gionchetti P, Eliakim R,
Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB,
Hart AL, Hindryckx P, et al: Third European evidence-based
consensus on diagnosis and management of ulcerative colitis. Part
1: Definitions, diagnosis, extra-intestinal manifestations,
pregnancy, cancer surveillance, surgery, and ileo-anal pouch
disorders. J Crohns Colitis. 11:649–670. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ţieranu CG, Dobre M, Mănuc TE, Milanesi E,
Pleşea IE, Popa C, Mănuc M, Ţieranu I, Preda CM, Diculescu MM, et
al: Gene expression profile of endoscopically active and inactive
ulcerative colitis: Preliminary data. Rom J Morphol Embryol.
58:1301–1307. 2017.PubMed/NCBI
|
|
20
|
Dobre M, Milanesi E, Mănuc TE, Arsene DE,
Ţieranu CG, Maj C, Becheanu G and Mănuc M: Differential intestinal
mucosa transcriptomic biomarkers for Crohn's disease and ulcerative
colitis. J Immunol Res. 2018(9208274)2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Milanesi E, Dobre M, Manuc T, Becheanu G,
Tieranu CG, Ionescu EM and Manuc M: Mucosal gene expression changes
induced by anti-TNF treatment in inflammatory bowel disease
patients. Drug Dev Res. 80:831–836. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Grimm MC and Doe WF: Chemokines in
inflammatory bowel disease Mucosa: Expression of RANTES, Macrophage
Inflammatory Protein (MIP)-1α, MIP-1β, and γ-Interferon-Inducible
Protein-10 by Macrophages, Lymphocytes, Endothelial Cells, and
Granulomas. Inflamm Bowel Dis. 2:88–96. 1996.PubMed/NCBI
|
|
24
|
Ajuebor MN, Hogaboam CM, Kunkel SL,
Proudfoot AE and Wallace JL: The chemokine RANTES is a crucial
mediator of the progression from acute to chronic colitis in the
rat. J Immunol. 166:552–558. 2001.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kristensen NN, Olsen J, Gad M and Claesson
MH: Genome-wide expression profiling during protection from colitis
by regulatory T cells. Inflamm Bowel Dis. 14:75–87. 2008.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Mayer L, Sandborn WJ, Stepanov Y, Geboes
K, Hardi R, Yellin M, Tao X, Xu LA, Salter-Cid L, Gujrathi S, et
al: Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: A
phase II randomised study. Gut. 63:442–450. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Dobre M, Manuc T, Milanesi E, Pleşea IE,
Ţieranu EN, Popa C, Mănuc M, Preda CM, Ţieranu I, Diculescu MM, et
al: Mucosal CCR1 gene expression as a marker of molecular activity
in Crohn's disease: Preliminary data. Rom J Morphol Embriol.
58:1263–1268. 2017.PubMed/NCBI
|
|
28
|
Trivedi PJ, Bruns T, Ward S, Mai M,
Schmidt C, Hirschfield GM, Weston CJ and Adams DH: Intestinal CCL25
expression is increased in colitis and correlates with inflammatory
activity. J Autoimmun. 68:98–104. 2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Singh UP, Venkataraman C, Singh R and
Lillard JW Jr: CXCR3 Axis: Role in inflammatory bowel disease and
its therapeutic implication. Endocrine Metab Immune Disord Targets.
7:111–123. 2007.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Singh UP, Singh NP, Murphy EA, Price RL,
Fayad R, Nagarkatti M and Nagarkatti PS: Chemokine and cytokine
levels in inflammatory bowel disease patients. Cytokine. 77:44–49.
2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Svensson M and Agace WW: Role of
CCL25/CCR9 in immune homeostasis and disease. Expert Rev Clin
Immunol. 2:759–773. 2006.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Vasilyeva E, Abdulkhakov S, Cherepnev G,
Martynova E, Mayanskaya I, Valeeva A, Abdulkhakov R, Safina D,
Khaiboullina S and Rizvanov A: Serum cytokine profiles in children
with Crohn's disease. Mediators Inflamm.
2016(7420127)2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Hosomi S, Oshitani N, Kamata N, Sogawa M,
Okazaki H, Tanigawa T, Yamagami H, Watanabe K, Tominaga K, Watanabe
T, et al: Increased numbers of immature plasma cells in peripheral
blood specifically overexpress chemokine receptor CXCR3 and CXCR4
in patients with ulcerative colitis. Clin Exp Immunol. 163:215–224.
2011.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Østvik AE, Granlund AV, Torp SH, Flatberg
A, Beisvåg V, Waldum HL, Flo TH, Espevik T, Damås JK and Sandvik
AK: Expression of Toll-like receptor-3 is enhanced in active
inflammatory bowel disease and mediates the excessive release of
lipocalin 2. Clin Exp Immunol. 173:502–511. 2013.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Uguccioni M, Gionchetti P, Robbiani DF,
Rizzello F, Peruzzo S, Campieri M and Baggiolini M: Increased
expression of IP-10, IL-8, MCP-1, and MCP-3 in Ulcerative Colitis.
Am J Pathol. 155:331–336. 1999.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Kolaczkowska E and Kubes P: Neutrophil
recruitment and function in health and inflammation. Nat Rev
Immunol. 13:159–175. 2013.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Le Y, Ye RD, Gong W, Li J, Iribarren P and
Wang JM: Identification of functional domains in the formyl peptide
receptor-like 1 for agonist-induced cell chemotaxis. FEBS J.
272:769–778. 2005.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Boulay F, Tardif M, Brouchon L and Vignais
P: Synthesis and use of a novel N-formyl peptide derivative to
isolate a human N-formyl peptide receptor cDNA. Biochem Biophys Res
Commun. 168:1103–1109. 1990.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Dorward DA, Lucas CD, Chapman GB, Haslett
C, Dhaliwal K and Rossi AG: The role of formylated peptides and
formyl peptide receptor 1 in governing neutrophil function during
acute inflammation. Am J Pathol. 185:1172–1184. 2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Leoni G, Gripentrog J, Lord C, Riesselman
M, Sumagin R, Parkos CA, Nusrat A and Jesaitis AJ: Human neutrophil
formyl peptide receptor phosphorylation and the mucosal
inflammatory response. J Leukoc Biol. 97:87–101. 2015.PubMed/NCBI View Article : Google Scholar
|
|
41
|
VanCompernolle SE, Clark KL, Rummel KA and
Todd SC: Expression and function of formyl peptide receptors on
human fibroblast cells. J Immunol. 171:2050–2056. 2003.PubMed/NCBI View Article : Google Scholar
|
